Molecular Profiling Project

Inclusion Criteria9

• The availability of sufficient archival tumor tissue specimen (15 slides of 4 microns per section)
• Age ≥ 21 years
• WHO performance status ≤ 2
• Life expectancy of ≥ 12 weeks
• Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment):
• Adequate bone marrow function as shown by: ANC ≥ 1.0 x 10\^9/L, Platelets ≥ 75 x 10\^9/L, Hb ≥ 7.5 g/dL
• Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or ≤3.0 x ULN if liver metastases are present)
• Willing to provide signed informed consent
• Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis with the study team, for potential enrolment